


MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs Placebo and Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis Patients

John Mascarenhas¹, Claire Harrison², Katarina Luptakova³, Jing Wang³, Gozde Colak³, James Shao³, Suresh Bobba³, Patrick Trojer³, Jeffrey Humphrey³, Srdan Verstovsek⁴,
on behalf of the MANIFEST-2 investigators.


¹Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States, ²Guy's and St. Thomas' Hospital, London, United Kingdom, ³Constellation Pharmaceuticals a MorphoSys Company, Cambridge, MA, United States, ⁴Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States

Background

BETi Pelabresib (CPI-0610) in MF




BETi CPI-0610 showed monotherapy activity in MF patients who are resistant/refractory, intolerant to ruxolitinib or ineligible for JAKi as evidenced by splenic response, symptoms improvement and Hgb improvement



Transfusion-dependence and Hemoglobin Improvement


- In transfusion-dependent cohort: 21% of patients converted to transfusion independence
- In nontransfusion-dependent cohort: 10/20 (50%) patients had 1.5 g/dL Hgb increase without transfusion

Mean Hemoglobin Over Time — All Patients¹



¹ Patients on treatment ≥ 12 wks


Combination of CPI-0610 + ruxolitinib leads to 67% SVR35 at Week 24 in JAKi-naïve pts (Poster MPN-332)



- Encouraging response rates were observed in spleen volume reduction (SVR35 response) and symptom improvement (TSS50 response) at Week 24 with the combination of CPI-0610 and ruxolitinib in JAKi-naïve MF patients — 67% SVR35 (primary endpoint) and 57% TSS50 responses at Week 24
- Based on these encouraging data from Phase 2 trial, the Phase 3, global, randomized, double-blind MANIFEST-2 trial of CPI-0610 + ruxolitinib vs placebo + ruxolitinib in a JAKi-naïve MF patient population has been initiated and is open for enrollment

Materials & Methods

MANIFEST-2 Phase 3 study



Key Eligibility Criteria

Inclusion Criteria

- Age ≥18 years old
- Confirmed diagnosis of myelofibrosis (primary, postpolycythemia vera or postessential thrombocythemia)
- Adequate hematologic, renal & hepatic function
- Have at least 2 symptoms with an average score ≥3 or an average total score of ≥10 over the 7-day period prior to randomization using the MFSAF v4.0
- Prognostic risk factor score of Intermediate-1 or higher per DIPSS
- Spleen volume of ≥450 cm³
- ECOG performance status ≤2

Exclusion Criteria

- Splenectomy or splenic irradiation in the previous 6 months
- Chronic or active conditions and/or concomitant medication use that would prohibit treatment
- Had prior treatment with any JAKi or BETi for treatment of a myeloproliferative neoplasm

MANIFEST Study SOHO 2021 Abstracts

- Poster MPN-328: Wednesday, September 8, 6:15–8:15 pm**

Pelabresib (CPI-0610) Improved Anemia Associated with Myelofibrosis: Interim Results from the Ongoing MANIFEST Phase 2 Study

- Poster MPN-332: Wednesday, September 8, 6:15–8:15 pm**

Clinical Benefit of Pelabresib (CPI-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study

- Poster MPN-343: Wednesday, September 8, 6:15–8:15 pm**

BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST Trial

MANIFEST-2 contact for study participation: debbie.johnson@constellationpharma.com